Tislelizumab plus chemo before surgery for MSS rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with MSS (microsatellite stable) rectal cancer that has not spread to other organs.
- The tumor is located in the lower part of the rectum – within 12 cm of the anus.
- Your cancer is at a locally advanced stage (T3/T4 or lymph node positive).
- You have not had any previous treatment for this cancer.
- Your overall health is good enough for chemotherapy and immunotherapy (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a combination of the immunotherapy drug tislelizumab with standard chemotherapy and radiation before surgery to see if it can help patients with low rectal cancer avoid surgery or keep their organs. It is for people whose tumors are close to the anus and have not spread.
This study tests whether combining mFOLFOX6 chemotherapy with an immunotherapy drug (anti-PD-1) before surgery can shrink locally advanced rectal cancer. It is open to people whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.